Fourth-quarter earnings are shaping up to be the best of 2023, but there's a catch

Fourth-quarter earnings are shaping up to be the best of 2023, but there's a catch


Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., February 1, 2024. 

Brendan McDermid | Reuters

Here’s how big of a surprise corporate profits have been this earnings season: the fourth-quarter is now shaping up to be the best of 2023.

Despite ongoing macroeconomic concerns that have hampered demand and weighed on consumer sentiment, almost halfway into earnings season, profits are clearly coming in far better than anybody expected.

Helping companies’ bottom lines this round: easing input costs; more emphasis on cost controls and efficiencies; and significantly reduced expectations.

A plethora of significant earnings beats among some very important S&P 500 companies like Amazon, Meta, Apple, Chevron, Exxon Mobil, Merck and Bristol-Myers Squibb have moved the Q4 growth rate notably higher late this week.

LSEG, formerly Refinitiv, is now seeing a nearly 8% rise in earnings growth this season. That’s far better than the 4.7% expected just three weeks ago, right before the big banks reported results.

Stronger-than-expected results from three sectors are particularly notable:

  • Energy – 90% of the companies have beat earnings estimates, with profits coming in almost 14% above expectations
  • Health Care – 85% have beat on the bottom line, with earnings coming in nearly 11% above expectations
  • Tech – 84% have posted earnings beats, with earnings more than 5% above expectations

As for the S&P 500 as a whole, Q4’s current EPS growth rate of 7.8% exceeds the 7.5% growth seen in all of Q3 – and is now tops for the year.

Currently, 80% of S&P 500 earnings results have beat estimates, slightly higher than normal trends, and earnings have come in more than 6% above expectations — not quite the 7% to 8% upside seen in the previous two quarters, but still a very strong number.

One very important caveat: These strong figures come after earnings expectations tumbled going into the reporting season. Back on October 1, S&P 500 fourth-quarter earnings were expected to grow 11% year over year, according to LSEG.

Although the earnings picture has significantly improved since the start of 2024, results are still far below what Wall Street had hoped for a mere four months ago.

And, as good as Q4 results have been, there’s still no positive momentum looking forward. Both Q1 and full-year 2024 earnings estimates have come down since January 1 as many companies have issued cautious guidance this earnings season.

— Charts by CNBC’s Gabriel Cortes.



Source

JPMorgan’s top biotech and pharma picks for the second half
Health

JPMorgan’s top biotech and pharma picks for the second half

Biopharmaceutical stocks’ underperformance versus the broader market for a third-straight year is an opportunity for investors, according to JPMorgan. Analyst Chris Schott said in the firm’s June outlook for biopharma that the sector’s poor performance can be traced back to concerns over President Donald Trump’s tariffs and his ” most favored nation ” executive order. […]

Read More
How twin sister triathletes doubled down on sports success to raise health-startup millions from investors
Health

How twin sister triathletes doubled down on sports success to raise health-startup millions from investors

During their last year of completing work for doctoral degrees in physiology, twin sisters Michal Mor and Merav Mor started to compete in Ironman triathlon races. The demand for peak fitness led them to the realize the importance of understanding personal metabolism, and the lack of data being collected on it through devices accessible to […]

Read More
It’s not just AI — China’s quickly gaining an edge over the U.S. in biotech
Health

It’s not just AI — China’s quickly gaining an edge over the U.S. in biotech

Two graduate students research chemical products in a laboratory in Xiwangzhuang Town, Zaozhuang City, Shandong province of China, on Dec. 26, 2023. Nurphoto | Nurphoto | Getty Images BEIJING — For all the attention on U.S.-China competition in artificial intelligence, new studies point to China’s rapid rise in biotechnology, especially for drug and agricultural development. […]

Read More